Excluding fuel, sales increased 1.1% compared to the same period last year.
Identical sales without fuel would have grown 2.6% in the second quarter if not for the reduction in pharmacy sales from the termination of our agreement with Express Scripts.
Second quarter net earnings were ($479) million including a $1.4 billion charge related to nationwide opioid settlement framework.
Adjusted EPS increased 7% compared to the same period last year. Second quarter net earnings per diluted share was ($0.25) including a $1.54 loss per share charge related to nationwide opioid settlement framework.
2022